Initiated with a Buy: Arcellx, Pliant Therapeutics, Tarsus Pharmaceuticals, Varonis Systems
- May 18th, 2023
- 171 views
Several companies have recently received initiations with Buy ratings from prominent financial institutions, indicating positive outlooks for their future performance.
Arcellx, Inc. (Nasdaq: ACLX) has been initiated with a Buy rating and a price target of $60 by Truist. In pre-market trading, $ACLX is currently trading at $41.34, with a slight increase of $0.10 (+0.24%).
Pliant Therapeutics, Inc. (Nasdaq: PLRX) has received a Buy rating from Canaccord Genuity, along with a price target of $48. $PLRX is trading at $21.75 in pre-market, showing a gain of $0.22 (+1.02%).
Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) has been initiated with a Buy rating by Guggenheim. In pre-market trading, $TARS is trading at $16.41, experiencing a significant increase of $0.48 (+3.01%).
Varonis Systems, Inc. (Nasdaq: VRNS) has received a Buy rating and a price target of $30 from DA Davidson. However, in pre-market trading, $VRNS is currently trading at $22.81, facing a decrease of $1.20 (-5.00%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Earnings Preview: Walt Disney, Applied Materials, and Celcuity Take Center Stage
November 11th, 2024Key Metrics: CyberArk Software, Hudbay Minerals, and Sonos Earnings Due
November 11th, 2024Earnings: What to Expect from Occidental Petroleum, Rocket Lab, and CAE
November 10th, 2024Earnings Countdown: Home Depot, Sea Limited, and Natera in the Spotlight
November 10th, 2024Ahead of Earnings: DoorDash, MetLife, and Exelon in the Spotlight
October 27th, 2024
Member Login